Compare CRWS & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRWS | ATOS |
|---|---|---|
| Founded | 1957 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.4M | 24.1M |
| IPO Year | 1994 | 2010 |
| Metric | CRWS | ATOS |
|---|---|---|
| Price | $2.96 | $2.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 103.2K | 55.0K |
| Earning Date | 02-11-2026 | 05-13-2026 |
| Dividend Yield | ★ 11.49% | N/A |
| EPS Growth | ★ 118.89 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $70,270,000.00 | $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.35 | ★ N/A |
| Revenue Growth | ★ 6.51 | N/A |
| 52 Week Low | $2.35 | $0.53 |
| 52 Week High | $3.17 | $7.56 |
| Indicator | CRWS | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 52.55 |
| Support Level | $2.88 | $0.58 |
| Resistance Level | $3.12 | $2.60 |
| Average True Range (ATR) | 0.11 | 0.19 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 85.23 | 48.11 |
Crown Crafts Inc operates in the infant and toddler products segment of the consumer products industry through its wholly-owned subsidiaries. The infant and toddler products segment consists of infant and toddler bedding, bibs, soft bath products, disposable products, and accessories. The company serves a diverse range of customers including mass merchants, mid-tier retailers, juvenile specialty stores, value channel stores, grocery and drug stores, restaurants, internet accounts, wholesale clubs, and internet-based retailers. The company's brands include NoJo, Neat Solutions, Sassy, and Carousel. Its products are marketed under a variety of company-owned trademarks, under trademarks licensed from others, and as private-label goods.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.